Well-designed Benzyl L-(+)-Mandelate - (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS 118864-75-8 Solifenacin Succinate Intermediate High Purity – Ruifu

Manufacturer with High Quality and Competitive Price
Commercial Supply Solifenacin Succinate (CAS: 242478-38-2) Related Intermediates:
Solifenacin Succinate CAS: 242478-38-2
(R)-(-)-3-Quinuclidinol CAS: 25333-42-0
(S)-(+)-3-Quinuclidinol CAS: 34583-34-1
3-Quinuclidinone Hydrochloride CAS: 1193-65-3
(R)-3-Quinuclidinol Hydrochloride CAS: 42437-96-7
1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 22990-19-8
(S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline (CAS: 118864-75-8) with high quality. (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline (CAS: 118864-75-8) is an intermediate typically in the synthesis of Solifenacin Succinate (CAS: 242478-38-2).

Solifenacin Succinate (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses.